0001437749-26-008259
SEC filingCervoMed Inc. reported a net loss of $27.0 million for fiscal year 2025, an increase from a $16.3 million loss in 2024. The company generated $4.0 million in grant revenue, a significant decrease from $9.7 million in the prior year. Research and development expenses increased to $21.8 million from $18.8 million, primarily driven by clinical trial activities for its lead drug candidate neflamapimod in Dementia with Lewy Bodies (DLB), frontotemporal disorders, and recovery after stroke. General and administrative expenses also rose to $10.5 million. The company ended the year with $20.9 million in cash, cash equivalents, and marketable securities, down from $38.9 million at the end of 2024. Management notes substantial doubt about the company's ability to continue as a going concern and will require additional capital to fund operations, including a planned Phase 3 trial in DLB.
CervoMed Inc. reported a net loss of $27.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $16.3 million in 2024. The company's grant revenue decreased to $4.0 million from $9.7 million year-over-year. Total operating expenses increased to $32.3 million from $28.0 million, driven by higher research and development costs. The company ended the year with $20.9 million in cash, cash equivalents, and marketable securities, a significant decrease from $38.9 million at the end of 2024. The accumulated deficit grew to $97.7 million. Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional capital.
The company's revenue consists entirely of grant funding from the National Institute on Aging (NIA) to support its RewinD-LB Trial. Grant revenue was $4.0 million in 2025, down from $9.7 million in 2024. The decrease reflects the timing of allowable expenses under the grant agreement. The company has received $20.5 million of the total $21.3 million NIA grant award as of December 31, 2025, with approximately $0.6 million remaining. No product revenue has been generated to date.
As a clinical-stage biotechnology company with no commercial products, CervoMed operates at a loss. The company's operating loss was $28.3 million in 2025 compared to $18.2 million in 2024. Research and development expenses increased to $21.8 million from $18.8 million, representing the majority of operating costs. General and administrative expenses also increased to $10.5 million from $9.2 million. The company's cost structure is heavily weighted toward clinical development activities, with personnel costs and clinical trial expenses being the primary drivers.
Net cash used in operating activities was $23.4 million in 2025, compared to $16.5 million in 2024. The company generated $18.1 million from investing activities through maturities of marketable securities, and $4.6 million from financing activities through an at-the-market equity offering. Total assets decreased to $22.9 million from $43.1 million, primarily due to the reduction in marketable securities. Total liabilities were $4.7 million, consisting mainly of accounts payable and accrued expenses. Stockholders' equity decreased to $18.2 million from $39.2 million. The company's liquidity position has weakened, with management noting that existing cash resources are insufficient to fund operations for at least twelve months.
CervoMed plans to initiate a Phase 3 clinical trial of neflamapimod for DLB in the second half of 2026, subject to available funding. The company anticipates several clinical development milestones in 2026, including completing enrollment in Phase 2a trials for nfvPPA and RAS, and initial biomarker data. Management acknowledges significant risks including the need for additional capital, clinical trial uncertainties, regulatory challenges, and competition. The company intends to seek funding through equity offerings, debt financings, or strategic collaborations but cannot guarantee availability on acceptable terms. If unable to raise sufficient capital, the company may need to delay, reduce, or terminate development activities.